Karakike, Eleni
Scicluna, Brendon P.
Roumpoutsou, Maria
Mitrou, Ioannis
Karampela, Niki
Karageorgos, Athanasios
Psaroulis, Konstantinos
Massa, Eleni
Pitsoulis, Achillefs
Chaloulis, Panagiotis
Pappa, Evanthia
Schrijver, Irene T.
Frantzeskaki, Frantzeska
Lada, Malvina
Dauby, Nicolas
De Bels, David
Floros, Ioannis
Anisoglou, Souzana
Antoniadou, Eleni
Patrani, Maria
Vlachogianni, Glykeria
Mouloudi, Eleni
Antoniadou, Anastasia
Grimaldi, David
Roger, Thierry
Wiersinga, W. Joost
Tsangaris, Iraklis
Giamarellos-Bourboulis, Evangelos J.
Funding for this research was provided by:
Horizon 2020 Framework Programme (676129, 676129, 676129, 676129, 676129, 676129)
Hellenic Institute for the Study of Sepsis
Article History
Received: 30 March 2022
Accepted: 8 June 2022
First Online: 18 June 2022
Declarations
:
: The study was conducted in accordance with the declaration of Helsinki and national and institutional standards. The protocol and informed consent form were approved in Greece [National Organization for Medicines (51239/01-06-2017), National Ethics Committee (52086/2017)] and Belgium [Federal Agency of Medicines and Health Products (1078386/16-04-2018), Central Ethics Committee, Erasme University Hospital (P2018/376, 19-10-2018)]. Study registration was with EudraCT (2017-001056-55) and Clinicaltrials.gov (NCT03345992). Written informed consent was provided by patients or legal representatives, prior to inclusion.
: Not applicable.
: E. Karakike is supported by the Horizon2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (grant number 676129- granted to the National and Kapodistrian University of Athens). I.T. Schrijver is supported by the Horizon2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (grant number 676129- granted to Lausanne University Hospital) and received a scholarship from the Société Académique Vaudoise (Lausanne, Switzerland). N. Dauby is a post-doctorate clinical master specialist of the Belgian F.R.S-FNRS and reports personal fees from Roche and Boehringer Ingelheim, and non-financial support from Pfizer, Janssen and Merck Sharp & Dohme, all outside the submitted work. T. Roger is funded by the European Union Horizon 2020 Marie Skłodowska-Curie Action Innovative Training Network European Sepsis Academy (ESA-ITN, grant number 676129) and by the European Union Horizon 2020 grant ImmunoSep (847422). W. J. Wiersinga is supported by the Netherlands Organization for Scientific Research (VIDI grant 91716475) and the Horizon2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” and received consulting fee paid to the host institution from MDS, GSK and Swedish Orphan Biovitrum AB. A. Antoniadou has received honoraria from Gilead, Pfizer, MSD, ViiV, BMS, Astellas and independent educational grants from Gilead, GSK and Biotest. D. Grimaldi received consultation fees from Transgene SA Illkirch-Graffenstaden (France). E. J. Giamarellos-Bourboulis has received honoraria from Abbott CH, bioMérieux, GSK, InflaRx GmbH, ThermoFisher Brahms GmbH, Sobi and XBiotech Inc; independent educational grants from Abbott CH, AxisShield, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi and XBiotech Inc.; and funding from the Horizon2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (granted to the National and Kapodistrian University of Athens); the Horizon 2020 European Grants ImmunoSep and RISC in COVID (granted to the Hellenic Institute for the Study of Sepsis); and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.